Skip to main content
Premium Trial:

Request an Annual Quote

Hyseq Hires New President, COO in Preparation to Begin Clinical Trials

NEW YORK, Jan 16 – Hyseq announced Tuesday the appointment of Ted Love as president and chief operating officer, signaling the company’s plans to enter the next stage of its drug development program.

"Hyseq has focused on selecting biopharmaceutical candidates from our thousands of full length genes during the past year, with the goal of moving two candidates into clinical trials as soon as possible. Ted brings significant experience and expertise to Hyseq to take these candidates into the clinic," George Rathmann, Hyseq’s chairman and CEO, said in a statement.

While Love will replace Rathmann in the capacity of president, Rathmann will remain chairman and CEO of the company. The position of COO was newly created for Love, who will also join Hyseq's board as a director.

Previously, Love was senior vice president of development at Advanced Medicine. He also worked in clinical research, product development, and regulatory affairs at Genentech.

In the past Hyseq has formed collaborations for developing gene-based products and for commercializing the HyChip biochip.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.